Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

122
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
122

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chinese Guidelines for Clinical Diagnosis, Treatment, and Management of Cirrhosis (2025).

Journal of clinical and translational hepatology·2026
Same author

Consensus on the Management of Liver Injury Associated with Targeted Drugs and Immune Checkpoint Inhibitors for Hepatocellular Carcinoma (Version 2024).

Journal of clinical and translational hepatology·2025
Same author

Quantitatively Evaluate the Improvement of Functional Cure for the Quality of Life of Chronic Hepatitis B Cases: Evidence from a Cross-Sectional Study in China.

Healthcare (Basel, Switzerland)·2025
Same author

Chinese Guidelines on the Management of Hepatic Encephalopathy in Cirrhosis (2024).

Journal of clinical and translational hepatology·2025
Same author

Chinese guidelines on the management of ascites in cirrhosis : Chinese Society of Hepatology, Chinese Medical Association.

Hepatology international·2024
Same author

Guidelines for the Management of Esophagogastric Variceal Bleeding in Cirrhotic Portal Hypertension.

Journal of clinical and translational hepatology·2024
Same journal

Correction to "Estrogen Protects against Renal Ischemia-Reperfusion Injury by Regulating Th17/Treg Cell Immune Balance".

Disease markers·2026
Same journal

RETRACTION: miR-127-5p Targets JAM3 to Regulate Ferroptosis, Proliferation, and Metastasis in Malignant Meningioma Cells.

Disease markers·2026
Same journal

RETRACTION: Thyroxine Alleviates Energy Failure, Prevents Myocardial Cell Apoptosis, and Protects against Doxorubicin-Induced Cardiac Injury and Cardiac Dysfunction via the LKB1/AMPK/mTOR Axis in Mice.

Disease markers·2026
Same journal

RETRACTION: Kartogenin Induced Adipose-Derived Stem Cell Exosomes Enhance the Chondrogenic Differentiation Ability of Adipose-Derived Stem Cells.

Disease markers·2026
Same journal

Correction to "KIF20A Affects the Prognosis of Bladder Cancer by Promoting the Proliferation and Metastasis of Bladder Cancer Cells".

Disease markers·2026
Same journal

RETRACTION: Antiresistin Neutralizing Antibody Alleviates Doxorubicin-Induced Cardiac Injury in Mice.

Disease markers·2026
See all related articles

Related Experiment Video

Updated: Dec 5, 2025

Measurement of Chitinase Activity in Biological Samples
03:32

Measurement of Chitinase Activity in Biological Samples

Published on: August 22, 2019

10.7K

Decrease in Chitinase 3-Like Protein 1 Levels Reflects Improvement in Liver Fibrosis after HCV Eradication.

Qian Kang1, Jianhong Chen2, Hao Luo1

  • 1Departments of Infectious Diseases, Peking University First Hospital, NO.8, Xishiku Street, Xicheng District, Beijing 100034, China.

Disease Markers
|October 21, 2020
PubMed
Summary
This summary is machine-generated.

Chitinase 3-like protein 1 (CHI3L1) effectively monitors liver fibrosis regression after hepatitis C virus (HCV) eradication. CHI3L1 indicates treatment success and potential progression, aiding clinical decisions.

More Related Videos

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
10:56

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

Published on: September 15, 2018

8.4K
Murine Precision-Cut Liver Slices as an Ex Vivo Model of Liver Biology
12:36

Murine Precision-Cut Liver Slices as an Ex Vivo Model of Liver Biology

Published on: March 14, 2020

17.1K

Related Experiment Videos

Last Updated: Dec 5, 2025

Measurement of Chitinase Activity in Biological Samples
03:32

Measurement of Chitinase Activity in Biological Samples

Published on: August 22, 2019

10.7K
A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
10:56

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

Published on: September 15, 2018

8.4K
Murine Precision-Cut Liver Slices as an Ex Vivo Model of Liver Biology
12:36

Murine Precision-Cut Liver Slices as an Ex Vivo Model of Liver Biology

Published on: March 14, 2020

17.1K

Area of Science:

  • Hepatology
  • Virology
  • Biomarker Research

Background:

  • Direct-acting antivirals (DAAs) have revolutionized hepatitis C virus (HCV) treatment.
  • Chitinase 3-like protein 1 (CHI3L1) is a known marker for liver fibrosis staging in HCV patients.

Purpose of the Study:

  • To evaluate CHI3L1 as a surrogate marker for dynamic hepatic fibrosis changes.
  • To compare fibrosis regression between sofosbuvir (SOF)-based regimens and pegylated interferon/ribavirin (PR) treatments.

Main Methods:

  • 105 patients were enrolled: 46 treated with SOF-based regimens, 34 with PR, and 25 untreated controls.
  • Serum samples and clinical data collected at baseline, end of treatment, and 24/48 weeks post-treatment.
  • CHI3L1 levels correlated with liver stiffness measurement (LSM) and liver cirrhosis diagnosis.

Main Results:

  • Serum CHI3L1 correlated significantly with LSM (r=0.615, P<0.001) and accurately diagnosed cirrhosis (AUC=0.939).
  • CHI3L1 levels decreased significantly after SOF-based treatment (P=0.001) and PR treatment (P=0.016).
  • Untreated patients showed increased CHI3L1 levels, indicating fibrosis progression (P=0.048).

Conclusions:

  • CHI3L1 is a sensitive biomarker for monitoring fibrosis variations during and after HCV treatment.
  • It can identify early treatment failure and monitor fibrosis progression, aiding in managing liver cirrhosis risk.